Clinical Trial Update: Talazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

This entry provides an update on a Phase 2 trial evaluating talazoparib in combination with low-dose temozolomide for relapsed or refractory extensive-stage sma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer Extensive Stage

Drugs mentioned

• Talazoparib (talazoparib)
• Temozolomide (Temozolomide)

Snippet

Sponsor: Jonsson Comprehensive Cancer Center | Conditions: Recurrent Extensive Stage Small Cell Lung Carcinoma, Refractory Extensive Stage Small Cell Lung Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING